Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schwarz Neupro "approvable"

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Schwarz' early-stage Parkinson's treatment Neupro (rotigotine transdermal system) is "approvable" pending submission of "additional analyses and summaries from the existing database," the firm announces March 1. "We anticipate responding to the action letter within six months," the company says. FDA's decision on the new molecular entity comes after the agency extended its user fee date by 90 days (1Pharmaceutical Approvals Monthly December 2005, p. 5). Schwarz plans to submit an sNDA for advanced Parkinson's by the end of 2006; Phase III results in restless legs syndrome are expected in the first quarter of 2007...

You may also be interested in...



Pfizer, Allergan And Schering NMEs Receive Second “Approvable” Letters

Pfizer’s anidulafungin received a second “approvable” letter Nov. 25 for treatment of esophageal candidiasis, FDA said.

Italy: Pharma May Have To Disclose Confidential Info Under New Pricing Rules

Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.

Sandoz Looks Ahead To Biosimilar Opportunities

Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel